GlassScriptPhysician profile
Muhammad Anis Memon
NPI 1780691923
$3,418.09
in general payments reported to CMS, 2019-2025
26 companies · $518 in 2025
The $518 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $531 · 2021: $564 · 2022: $471 · 2023: $210 · 2024: $886 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582 · Education: $32.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.51 |
| Education | $32.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.37 | 2020-2025 | |
| Ethicon US, LLC | $361.53 | 2019-2022 | |
| Boston Scientific Corporation | $217.07 | 2019-2025 | Overstitch Endoscopic Suturing System |
| Janssen Biotech, INC. | $193.20 | 2021-2025 | Simponi Aria, Simponi, Remicade |
| Pfizer INC. | $169.37 | 2019-2025 | |
| Stryker Corporation | $168.44 | 2024 | Trevo, Target |
| Asahi Intecc USA, INC. | $160.80 | 2024 | Peripheral Vascular |
| Braintree Laboratories, INC. | $158.52 | 2020-2025 | Sutab, Suflave |
| Vivus LLC | $131.95 | 2023-2025 | Qsymia, Pancreaze |
| Merck Sharp & Dohme LLC | $95.91 | 2022-2024 | Dificid |
| Covidien LP | $84.46 | 2020 | |
| Phathom Pharmaceuticals, INC. | $83.07 | 2024 | Voquezna |
| Celltrion USA INC. | $76.65 | 2024-2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $72.18 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $48.85 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.32 | 2019-2023 | Xifaxan |
| Alfasigma USA, INC. | $33.64 | 2020 | |
| Erbe USA INC | $30.00 | 2020 | |
| Medtronic, INC. | $28.27 | 2022 | |
| Redhill Biopharma INC. | $27.55 | 2022 | |
| Celgene Corporation | $27.26 | 2021-2022 | |
| Ardelyx, INC. | $22.99 | 2025 | Ibsrela |
| Qol Medical, LLC | $18.32 | 2022 | |
| Evoke Pharma, INC. | $15.93 | 2023 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2021 | |
| Allergan, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.